Treatment of IgG4-Related Disease With Revlimid and Rituximab
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who
have persistent or recurrent disease despite standard therapies, does combination therapy
with rituximab and revlimid cause a sustained disease remission?